Is Trillium Therapeutics Inc (TRIL) Stock a Good Buy in Biotechnology – InvestorsObserver

Trillium Therapeutics Inc (TRIL) is near the top in its industry group according to InvestorsObserver. TRIL gets an overall rating of 93. That means it scores higher than 93 percent of stocks. Trillium Therapeutics Inc gets a 99 rank in the Biotechnology industry. Biotechnology is number 64 out of 148 industries.

Click Here to get the full Stock Score Report on Trillium Therapeutics Inc (TRIL) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trillium Therapeutics Inc (TRIL) stock is trading at $1.32 as of 10:16 AM on Friday, Jan 3, a drop of -$0.17, or -11.4% from the previous closing price of $1.49. The stock has traded between $1.21 and $1.40 so far today. Volume today is light. So far 1,222,468 shares have traded compared to average volume of 1,841,439 shares.

To see the top 5 stocks in Biotechnology click here.

See original here:
Is Trillium Therapeutics Inc (TRIL) Stock a Good Buy in Biotechnology - InvestorsObserver